Invitrogen

Human CDR2 (aa 270-392) Control Fragment Recombinant Protein

Product Details

RP-91639

Applications

Tested Dilution

Publications

Control (Ctrl)

Assay-dependent

Blocking Assay (BLOCK)

Assay-dependent

Product Specifications

Species

Human

Expression System

E. coli

Amino acid sequence

GVEKLVPDSLYVPFKEPSQSLLEEMFLTVPESHRKPLKRSSSETILSSLAGSDIVKGHEETCIRRAKAVKQRGISLLHEVDTQYSALKVKYEELLKKCQEEQDSLSHKAVQTSRAAAKDLTGV

Tag

His-ABP-tag

Class

Recombinant

Type

Protein

Purity

>80% by SDS-PAGE and Coomassie blue staining

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

≥5.0 mg/mL

Purification

purified

Storage buffer

PBS/1M urea, pH 7.4

Contains

no preservative

Storage conditions

-20°C, Avoid Freeze/Thaw Cycles

Product Specific Information

Highest antigen sequence indentity to the following orthologs: Mouse (88%), Rat (88%).

This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-53741. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.

Target Information

Using anti-Yo antibodies, three genes have been cloned (CDR 1-3). CDR2 suppresses the transcriptional activity and DNA binding of nuclear factor-kappa B by an unknown mechanism. The neuron specific expression of CDR2 is regulated by a post-transcriptional mechanism.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

References (0)

Have you cited this product in a publication?

Let us know so we can reference it here.

Cite this product

Bioinformatics

Protein Aliases: Cerebellar degeneration-related protein 2; cerebellar degeneration-related protein 2, 62kDa; Major Yo paraneoplastic antigen; Paraneoplastic cerebellar degeneration-associated antigen; Yo paraneoplastic antigen